Cutaneous cancers are, by far, the most common malignant neoplasms of the human being. Due to the great array of clinical conditions, their worldwide increasing incidence and the steady ageing of the population, non-invasive treatments modalities that show a good clinical response, a proper benefit–risk ratio and cosmetic results are becoming increasingly important in the clinical setting. Imiquimod is a topically applied immunomodulator which is often used in the management of several premalignant and malignant cutaneous disorders. This article is a review of the current literature on its mechanism of action, pharmacokinetics, and therapeutical effects.

Four patients with extensive tinea infections caused by Trichophyton indotineae, resistant to terbinafine and partially responsive to itraconazole, were successfully treated with posaconazole after molecular identification confirmed T. indotineae. Given the growing terbinafine resistance associated with this pathogen, particularly in travellers from endemic areas, antifungal susceptibility testing is critical. Posaconazole, although not typically indicated for dermatophytoses, demonstrated complete resolution in these cases, highlighting its potential as an alternative treatment for resistant tinea infections.